Skip to main navigation
Skip to main content

Utility Nav Header

  • Contact
  • Twitter
  • LinkedIn

Main navigation

  • About
    • Our Focus
    • CEO Video
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Responsibility
      • Corporate Governance
      • Diversity & Inclusion
      • Corporate Giving
  • Our Science
    • Our Approach
    • Pipeline
      • Pipeline
      • Repotrectinib
      • Elzovantinib (TPX-0022)
      • TPX-0046
      • TPX-0131
    • Publications & Presentations
  • Clinical Trials
    • Company Trials
    • Compassionate Use
    • Investigator Sponsored Research
  • Investors
    • Overview
    • Press Releases
    • Events
    • Presentations
    • SEC Filings
    • Quarterly Results
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Leadership
      • Committee Composition
    • Investor Contact
    • Email Alerts
  • Careers
    • Vision, Mission & Values
    • Our Culture
    • Diversity & Inclusion
    • Opportunities
    • Our Hiring Process
    • Benefits

Quarterly Results

Show all

2022

Q1

  • Turning Point Therapeutics Reports First-Quarter 2022 Financial Results, Provides Operational Updates

2021

Q4

  • Turning Point Therapeutics Reports Fourth-Quarter and Full Year 2021 Financial Results, Provides Operational Updates
  • Form 10-K

Q3

  • Turning Point Therapeutics Reports Third-Quarter Financial Results, Provides Operational Updates
  • Turning Point Therapeutics Third Quarter 2021 Conference Call
  • Form 10-Q

Q2

  • Turning Point Therapeutics Reports Second-Quarter Financial Results, Provides Operational Updates
  • Turning Point Therapeutics Second Quarter 2021 Conference Call
  • Form 10-Q

Q1

  • Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Operational Updates
  • Turning Point Therapeutics First Quarter 2021 Conference Call
  • Form 10-Q

2020

Q4

  • Turning Point Therapeutics Reports Fourth-Quarter and Full-Year Financial Results, Provides Operational Updates
  • Turning Point Therapeutics Fourth Quarter 2020 Conference Call
  • Form 10-K

Q3

  • Turning Point Therapeutics Reports Third-Quarter Financial Results, Provides Operational Updates
  • Form 10-Q

Q2

  • Turning Point Therapeutics Reports Second-Quarter Financial Results, Provides Operational Updates
  • Form 10-Q

Q1

  • Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Update on Operations and COVID-19 Response
  • Turning Point Therapeutics First Quarter 2020 Conference Call
  • Form 10-Q
Copyright © 2022 Turning Point Therapeutics, Inc. | All Rights Reserved | Sitemap | Terms of Use | Privacy Policy Statement